The pharmacokinetics and safety of intravenous voriconazole - A novel wide-spectrum antifungal agent

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 2-9

  Purkins, Lynn ^a   Wood, Nolan ^a   Greenhalgh, Katie ^a   Eve, Malcolm D ^b   Oliver, Stuart D ^c   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Besselaar Clinical Research Unit   (United Kingdom)

Author keywords

Intravenous; Pharmacokinetics; Safety; Tolerability; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; VORICONAZOLE;

ADULT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SALIVA LEVEL; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INJECTION PAIN; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN DISEASE; SOMNOLENCE; STEADY STATE; STOMATITIS; SWEAT GLAND DISEASE; TOOTH DISEASE; VASODILATATION; VERTIGO; VISUAL DISORDER;

EID: 0345374650     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01992.x     Document Type: Article

References (10)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
8. SAS/STAT user's guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
9. Verweij PE, de Pauw BE, Meis JF. Voriconazole. Curr Opin Anti-Infect Invest Drugs 1999; 1: 361-372.
10. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553.